CURR - CURE Pharmaceutical launches two new clinical development programs

CURE Pharmaceutical (CURR) announces that it has launched two new clinical development programs and added new corresponding products to its pharmaceutical pipeline.The first is an antiviral clinical development program where CURE will look to load a known active pharmaceutical ingredient ((API)) onto its patented drug delivery platform CUREfilm.The second pipeline product addition uses a similar bioequivalence approach where the company will formulate the delivery of a known anti-seizure API for both adult and pediatric indications.Both the programs will leverage existing pre-clinical/clinical safety and toxicity data to develop orally bioavailable products and expand CURE’s pharmaceutical research & development efforts toward building a specialty pharmaceutical pipeline.

For further details see:

CURE Pharmaceutical launches two new clinical development programs